Recombinant Human IL-29/IFN-lambda 1 Protein

• Reactivity: Hu
• Applications: PAGE, Bioactivity
• Format: Carrier-Free
• Concentration: LYOPH

Recombinant Human IL-29/IFN-lambda 1 Protein Summary

• Description: A single non-glycosylated polypeptide chain containing 181 amino acids corresponding to IL-29/IFN-lambda 1 Source: E. coli

  Uniprot ID: Q8IU54

  Amino Acid Sequence: GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T

• Details of Functionality: Fully biologically active when compared to standard. The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity of > 2.0 x 10^5 IU/mg.
• Source: E. coli
• Protein/Peptide Type: Recombinant Protein
• Gene: IFNL1
• Purity: > 97 % pure by SDS-PAGE and HPLC
• Endotoxin Note: Less than 1 EU/ug of IL-29/IFN-lambda 1 as determined by LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • SDS-Page
• Theoretical MW: 19.8 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at -20 to -70C as supplied. After reconstitution, store at 2 to 8C for 1 month and at -20 to -70C for long term storage. Avoid repeated freeze-thaw cycles.
• Buffer: Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4.
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: > 97 % pure by SDS-PAGE and HPLC
• Reconstitution Instructions: Recommended to centrifuge prior to opening. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/mL.

Alternate Names for Recombinant Human IL-29/IFN-lambda 1 Protein

• cytokine Zcyto21
• IFNL1
• IFN-lambda 1
• IFN-lambda1
• IFN-lambda-1
• IFN-lambda1/IL-29
• IL29
• IL-29
• interferon lambda-1
• interferon, lambda 1
• interleukin 29 (interferon, lambda 1)
• interleukin-29
• ZCYTO21

Background

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13% a.a. sequence identity) and the type IIFN family (15-19 % a.a. sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or doublestranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and upregulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor lambda (IL-10 R beta) and a novel IL-28 receptor alpha (IL-28 R alpha, also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: IFNL1
• Uniprot:
  • Q8IU54()
  • Q8IU54()
  • Q8IU54()